BLAINJECTIONINJECTABLE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
SIMPONI ARIA (golimumab) by Johnson & Johnson is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2013.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMPONI ARIA (golimumab) is a monoclonal antibody that blocks tumor necrosis factor (TNF), a key driver of inflammation in autoimmune diseases. Administered as an intravenous injection, it is indicated for patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other TNF-mediated conditions. The drug works by neutralizing TNF receptors, reducing inflammatory signaling and disease progression.
$39MPart D
PeakStable
SIMPONI ARIA is at peak market penetration with stable spending; teams are focused on market maintenance and physician engagement across multiple indications.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Started May 2024
8 enrolled
Metastatic Castration-Resistant Prostate CarcinomaProstate AdenocarcinomaStage IV Prostate Cancer AJCC v8
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Started Jul 2023
63 enrolled
Psoriatic Arthritis
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Started Sep 2022
577 enrolled
Colitis, Ulcerative
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Started Jul 2022
703 enrolled
Crohn's Disease
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Started Oct 2021
91 enrolled
Arthritis, Psoriatic
Worked on SIMPONI ARIA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.